Immune checkpoint inhibitor therapy targeting CTLA-4 or programmed cell death protein 1 (PD-1) and its ligand (PD-L1) and targeted therapy with kinase inhibitors (BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors) are the current standard treatments for melanoma [4]. This evidence concerns the gene MAP2K7 and melanoma.